Filing Flows › electroCore (ECOR) › Guidance & outlook
electroCore (ECOR) guidance and outlook
electroCore (ECOR) narrowed its guidance on Nov 4, 2026: Net income $1.3M–$2.0M for FY2026; Net income +61% for FY2026; EBITDA $700K–$1.4M for FY2026; EBITDA +67% for FY2026. electroCore's 10-Q filed Nov 4, 2026 makes 14 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Net income | FY2026 | $1.3M–$2.0M | new |
| Net income | FY2026 | +61% | new |
| EBITDA | FY2026 | $700K–$1.4M | new |
| EBITDA | FY2026 | +67% | new |
| Revenue | FY2026 | $39.0M–$42.0M | new |
| Revenue | FY2026 | +30% | reaffirmed |
| Revenue | FY2027 | +30% to +40% | initiated |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Although we may choose to relaunch the Quell OTC product in the direct-to-consumer business channel in the future, there can be no assurance that we will do so successfully, or at all.
- In addition, uncertainty during a transition may affect employee morale and retention, including among key personnel, and there is a risk that institutional knowledge is lost during the leadership change, which could impact our ability to manage ongoing projects, maintain customer relationships, and achieve our strategic objectives.
- We intend to remain focused on continuity of execution and disciplined prioritization as we navigate this transition, while continuing to evaluate the opportunities and challenges that may affect our business, results of operations, and financial condition.
- Our expected cash requirements for the next 12 months and beyond are based on the commercial success of our products.
- There can be no assurance that we will have sufficient cash flow and liquidity to fund our planned activities, which could force us to significantly reduce or curtail our activities and, ultimately, potentially cease operations.
- The proposed maximum offering price per unit and the proposed maximum aggregate offering price per class of security in any future offering under the 2025 Shelf Registration Statement will be determined from time to time by us in connection with the issuance by us of the securities registered under the 2025 Shelf Registration Statement.
- The Company intends to use the net proceeds from any offering pursuant to the Sales Agreement to continue to fund sales and marketing, working capital and for other general corporate purposes.
- We prepare our condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods.
- We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our…
- We expect that the majority of 2026 fiscal year revenue will continue to come from sales of our Rx products to the VA.
- We have experienced significant net losses, and we expect to continue to incur net losses for the near future as we work to increase market acceptance of our products.
- During the remainder of 2026, we intend to continue to make targeted investments in sales, marketing, and research and development to continue driving commercial activities.
electroCore's latest quarter
electroCore, Q3 2026: revenue $9.7M (+12% year over year), operating margin -16.1%, net loss $1.3M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
Questions
Did electroCore raise or lower its guidance?
electroCore (ECOR) narrowed its guidance on Nov 4, 2026: Net income $1.3M–$2.0M for FY2026; Net income +61% for FY2026; EBITDA $700K–$1.4M for FY2026; EBITDA +67% for FY2026.
What does electroCore expect?
Although we may choose to relaunch the Quell OTC product in the direct-to-consumer business channel in the future, there can be no assurance that we will do so successfully, or at all. In addition, uncertainty during a transition may affect employee morale and retention, including among key personnel, and there is a risk that institutional knowledge is lost during the leadership change, which could impact our ability to manage ongoing projects, maintain customer relationships, and achieve our strategic objectives. We intend to remain focused on continuity of execution and disciplined prioritiz
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.